Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nucor Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Nucor Corporation trades at $250.33 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 73.1× Ginkgo Bioworks Holdings Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Nucor Corporation for 78 Days on average.
| DNA | NUE | |
|---|---|---|
Market Cap | $763.64M | $55.84B |
Volume | 3,204,177 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $274.74 |
52-Week Low | $5.48 | $131.78 |
Typical Hold Time | 7 Days | 78 Days |
Enterprise Value | $865.59M | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with a moderate buy analyst consensus and a $266.88 price target. Revenue rebounded to $32.49B in 2025, though net margins have compressed from 2022 peaks. Recent news highlights steel sector volatility and Nucor's Q3 2026 guidance projecting higher earnings on improved pricing.
Outlook remains cautiously optimistic with earnings growth potential from steel price strength and operational efficiency, balanced by competitive pressures from new capacity and cyclical demand risks. The stock offers value at a P/E of 19.64 and a solid dividend history, but investors face headwinds from margin pressure and industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
